ALK and lung adenocarcinoma: In summary, we studied on 72 patients in stage IV lung adenocarcinoma in Hubei province and investigated the predictive value of serum tumor markers in the prediction of ALK mutations, which we cannot predict through the level of tumor markers (SCCAg, CYRF21‐1, and NSE).